Cho Namki, Lee Hee Kyoung, Jeon Byung Ju, Kim Hyeon Woo, Kim Hong Pyo, Lee Jong-Hwan, Kim Young Choong, Sung Sang Hyun
College of Pharmacy and Research Institute of Pharmaceutical Science, Seoul National University, Seoul 151-742, Republic of Korea.
Institute for Life Science, Elcom Science Co. Ltd., Seoul, Republic of Korea.
Food Chem Toxicol. 2014 Dec;74:156-63. doi: 10.1016/j.fct.2014.09.019. Epub 2014 Oct 6.
Alzheimer's disease (AD) is closely associated with amyloid β (Aβ)-induced neurotoxicity and oxidative stress in the brain. Betula platyphylla, which has been used to treat various oxidative-stressed related diseases, has recently received attention for its preventive activity on age-related neurodegenerative diseases. In this study, we attempted to investigate the effects of B. platyphylla bark (BPB-316) on Aβ(1-42)-induced neurotoxicity and memory impairment. Oral treatment using BPB-316 significantly attenuated Aβ-induced memory impairment which was evaluated by behavioral tests including the passive avoidance, Y-maze and Morris water maze test. BPB-316 also inhibited the elevation of β-secretase activity accompanying the reduced Aβ(1-42) levels in the hippocampus of the brain. Furthermore, BPB-316 significantly decreased the acetylcholinesterase activity and increased the glutathione content in the hippocampus. In addition, we confirmed that the expression of both cAMP responsive element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) in the hippocampus of Aβ(1-42)-injected mice were markedly upregulated by the treatment of BPB-316. Our data suggest that the extracts of B. platyphylla bark might be a potential therapeutic agent against AD.
阿尔茨海默病（AD）与大脑中淀粉样蛋白β（Aβ）诱导的神经毒性和氧化应激密切相关。白桦已被用于治疗各种与氧化应激相关的疾病，最近其对年龄相关性神经退行性疾病的预防活性受到关注。在本研究中，我们试图研究白桦树皮（BPB - 316）对Aβ（1 - 42）诱导的神经毒性和记忆障碍的影响。通过包括被动回避、Y迷宫和莫里斯水迷宫试验在内的行为测试评估，使用BPB - 316进行口服治疗可显著减轻Aβ诱导的记忆障碍。BPB - 316还抑制了大脑海马体中β - 分泌酶活性的升高，同时降低了Aβ（1 - 42）水平。此外，BPB - 316显著降低了海马体中的乙酰胆碱酯酶活性并增加了谷胱甘肽含量。另外，我们证实，用BPB - 316处理可使注射Aβ（1 - 42）的小鼠海马体中cAMP反应元件结合蛋白（CREB）和脑源性神经营养因子（BDNF）的表达均显著上调。我们的数据表明，白桦树皮提取物可能是一种潜在的抗AD治疗药物。
